Solvay Submits Cilansetron NDA For Irritable Bowel Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
Assuming a standard review clock, cilansetron’s user fee date would be May 1, 2005. The application for use in diarrhea-predominant IBS includes an “extensive appropriate use plan,” Solvay says. The drug’s proposed trade name is Calmactin.